In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.
Ikenna Madueke, MD, PhD
Advertisement
Articles by Ikenna Madueke, MD, PhD
Advertisement
Latest Updated Articles
Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?Published: June 19th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Adjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
2
Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer
3
Salvage Nodal Radiation Shows Tolerability, Low Toxicity in Prostate Cancer
4
Managing BCMA/GPRC5D-Associated CRS and ICANS in the Real-World Setting
5
